Generate Biomedicines (NASDAQ:GENB) Earns Overweight Rating from Analysts at Morgan Stanley

Morgan Stanley started coverage on shares of Generate Biomedicines (NASDAQ:GENB) in a research report sent to investors on Tuesday, MarketBeat Ratings reports. The firm issued an overweight rating and a $20.00 price target on the stock.

Several other equities analysts have also commented on GENB. The Goldman Sachs Group started coverage on shares of Generate Biomedicines in a research report on Tuesday. They issued a “buy” rating and a $26.00 price objective for the company. Guggenheim began coverage on Generate Biomedicines in a research note on Tuesday. They issued a “buy” rating and a $30.00 target price for the company. Wall Street Zen raised Generate Biomedicines to a “hold” rating in a research report on Saturday, March 14th. Finally, Cantor Fitzgerald started coverage on Generate Biomedicines in a report on Tuesday. They issued an “overweight” rating on the stock. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $25.00.

Generate Biomedicines Price Performance

Shares of GENB stock opened at $12.85 on Tuesday. Generate Biomedicines has a 12-month low of $11.00 and a 12-month high of $15.32.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.